In 2022, many new therapies and tests for cancer were approved, but a significant number of patients are still not receiving appropriate therapies. Suboptimal testing paradigms, reimbursement issues and physicians’ inability to keep up with rapidly advancing...
In the summer of 2019, a genetic counselor at an academic healthcare facility saw a 39-year-old African American woman who had been recently diagnosed with invasive ductal carcinoma. A mammogram and subsequent biopsy of the lump she had felt on her left breast turned...
